JP2023551145A5 - - Google Patents

Info

Publication number
JP2023551145A5
JP2023551145A5 JP2023529879A JP2023529879A JP2023551145A5 JP 2023551145 A5 JP2023551145 A5 JP 2023551145A5 JP 2023529879 A JP2023529879 A JP 2023529879A JP 2023529879 A JP2023529879 A JP 2023529879A JP 2023551145 A5 JP2023551145 A5 JP 2023551145A5
Authority
JP
Japan
Prior art keywords
complexing agent
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023529879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551145A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/059760 external-priority patent/WO2022109050A1/en
Publication of JP2023551145A publication Critical patent/JP2023551145A/ja
Publication of JP2023551145A5 publication Critical patent/JP2023551145A5/ja
Pending legal-status Critical Current

Links

JP2023529879A 2020-11-18 2021-11-17 医薬化合物の錯化剤塩製剤 Pending JP2023551145A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063115451P 2020-11-18 2020-11-18
US202063115453P 2020-11-18 2020-11-18
US202063115458P 2020-11-18 2020-11-18
US202063115445P 2020-11-18 2020-11-18
US63/115,451 2020-11-18
US63/115,458 2020-11-18
US63/115,445 2020-11-18
US63/115,453 2020-11-18
PCT/US2021/059760 WO2022109050A1 (en) 2020-11-18 2021-11-17 Complexing agent salt formulations of pharmaceutical compounds

Publications (2)

Publication Number Publication Date
JP2023551145A JP2023551145A (ja) 2023-12-07
JP2023551145A5 true JP2023551145A5 (cg-RX-API-DMAC7.html) 2024-11-26

Family

ID=81709677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023529879A Pending JP2023551145A (ja) 2020-11-18 2021-11-17 医薬化合物の錯化剤塩製剤

Country Status (5)

Country Link
US (2) US11534454B2 (cg-RX-API-DMAC7.html)
EP (1) EP4247340A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023551145A (cg-RX-API-DMAC7.html)
CA (1) CA3198795A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022109050A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3968979B1 (en) 2019-05-15 2026-07-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
EP4161503A4 (en) 2020-06-08 2024-07-03 Tactogen Inc. Advantageous benzofuran compositions for mental disorders or enhancement
TW202216676A (zh) 2020-07-06 2022-05-01 美商塔朵根公司 用於心理疾病或心理強化的有益苯并噻吩組合物
AU2021322291A1 (en) 2020-08-06 2023-04-06 Tactogen Inc 2-aminoindane compounds for mental disorders or enhancement
EP4247340A4 (en) 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
WO2022204323A1 (en) * 2021-03-24 2022-09-29 The Trustees Of Columbia University In The City Of New York Non-hallucinogenic ariadne analogs for treatment of neurological and psychiatric disorders
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
EP4525916A4 (en) * 2022-05-18 2026-05-20 Bexson Biomedical Inc LOW STOICHIOMETRIC RATIO SALT FORMULATIONS FOR COMPLEXING AGENTS OF PHARMACEUTICAL COMPOUNDS
IN202221054235A (cg-RX-API-DMAC7.html) 2022-09-22 2023-11-03
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
EP4431083A1 (en) * 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
AU2024284688A1 (en) * 2023-06-06 2025-12-11 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
CN116769070B (zh) * 2023-06-07 2025-07-01 浙江工业大学 一种功能化磁性纳米颗粒及作为手性萃取剂在液-液萃取拆分手性化合物中的应用
EP4773958A1 (en) * 2023-09-08 2026-07-15 ATAI Therapeutics, Inc. Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
WO2025111482A1 (en) * 2023-11-22 2025-05-30 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
SE501482C2 (sv) 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
JP3283713B2 (ja) * 1993-12-06 2002-05-20 武田薬品工業株式会社 水溶性の改善された水不溶性ないし難溶性化合物含有組成物
DE69425948T2 (de) * 1993-12-06 2001-02-22 Takeda Chemical Industries, Ltd. Zusammensetzung mit verbesserter Wasserlöslichkeit, enthaltend eine Wasserunlösliche oder an Wasser schwerunlösliche Verbindung
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
ES2257795T3 (es) 1997-07-01 2006-08-01 Pfizer Products Inc. Procedimiento para producir una ciclodextrina.
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
IT1303735B1 (it) * 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
CN1172908C (zh) 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
US6348777B1 (en) 2000-02-29 2002-02-19 Alaris Medical Systems, Inc. Power management system
EP1383445A4 (en) 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
NZ537995A (en) * 2002-08-20 2007-11-30 Bristol Myers Squibb Co Inclusion complex of aripiprazole in a substituted b-cyclodextrin
AU2004260884B2 (en) 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
KR20060115350A (ko) * 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
KR20060113737A (ko) 2003-12-22 2006-11-02 쉐링 코포레이션 약제학적 조성물
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
KR20080080087A (ko) * 2005-09-30 2008-09-02 티티아이 엘뷰 가부시키가이샤 신규 약학 담체를 이용한 경피 약물 전달시스템, 장치 및방법
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
CA2698038A1 (en) 2007-07-26 2009-01-29 Entra Pharmaceuticals Inc. Systems and methods for delivering drugs
US8492538B1 (en) * 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
JP5785175B2 (ja) * 2009-10-26 2015-09-24 石葯集団中奇制葯技▲術▼(石家庄)有限公司 スルホブチルエーテルシクロデキストリン塩を含有する内水相を有するリポソーム
US20120295893A1 (en) 2009-12-14 2012-11-22 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
ITRM20100630A1 (it) 2010-12-03 2012-06-04 Dyepower Procedimento di sintesi di complessi precursori e sensibilizzatori del biossido di titanio basati su complessi polipiridinici di rutenio.
EP2653479B1 (en) 2010-12-16 2015-12-02 Sumitomo Seika Chemicals Co. Ltd. Method for producing pseudopolyrotaxane aqueous dispersion
AU2012221704B2 (en) 2011-02-23 2013-12-05 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
JP6296985B2 (ja) 2011-10-14 2018-03-20 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における(2r,6r)−ヒドロキシノルケタミン、(s)−デヒドロノルケタミン及び他の(r,s)−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20130296437A1 (en) 2012-05-04 2013-11-07 E-Therapeutics Plc Treatment of Depression
CN104520326A (zh) 2012-06-21 2015-04-15 Ucb医药有限公司 药物制剂
US10124940B2 (en) 2012-09-11 2018-11-13 Zolo Solutions, Inc. Systems, methods, and devices for dispensing one or more substances
WO2014121235A2 (en) 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
US9446186B2 (en) 2013-03-01 2016-09-20 Bigfoot Biomedical, Inc. Operating an infusion pump system
CN105437676B (zh) 2014-08-14 2020-03-24 上海利统生化制品有限公司 用于阻碍植物乙烯反应的层合物及其制备方法
FR3032353B1 (fr) 2015-02-06 2017-03-10 Jacques Seguin Composition pharmaceutique et dispositif pour le traitement de la douleur
CN108601891B (zh) 2016-01-12 2022-05-13 输液创新有限公司 输注设备
AU2017250086A1 (en) 2016-04-11 2018-09-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
WO2017218918A1 (en) * 2016-06-17 2017-12-21 Ys Pharmtech Stabilization of epinephrine formulations
DE102016014603A1 (de) * 2016-06-30 2018-01-04 Thomas Herkenroth Synthetisches Ayahuasca
SG11201901147TA (en) 2016-08-25 2019-03-28 Validose Inc System and method for controlled medical therapy
BR102017016440A2 (pt) * 2017-07-31 2019-03-19 Universidade Federal Do Rio Grande Do Sul Composição para terapia gênica do sistema nervoso central, processo de obtenção e uso da mesma
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
US20200384188A1 (en) 2017-11-14 2020-12-10 Bexson Biomedical, Inc. Systems, devices, formulations and methods for controlled drug delivery
CN111330019B (zh) 2018-12-18 2022-03-15 中国人民解放军第二军医大学 氟马西尼包合物及其制备方法和应用
EP3968979B1 (en) 2019-05-15 2026-07-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
US12576026B2 (en) 2020-07-08 2026-03-17 Extrovis Ag Formulations of nebivolol
EP4247340A4 (en) 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
EP4247386A4 (en) * 2020-11-18 2024-12-18 Bexson Biomedical, Inc. FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS
EP4525916A4 (en) 2022-05-18 2026-05-20 Bexson Biomedical Inc LOW STOICHIOMETRIC RATIO SALT FORMULATIONS FOR COMPLEXING AGENTS OF PHARMACEUTICAL COMPOUNDS
WO2025111482A1 (en) 2023-11-22 2025-05-30 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios

Similar Documents

Publication Publication Date Title
JP3743449B2 (ja) 4,5−エポキシモルヒナン誘導体を含有する安定なソフトカプセル剤
ES2661574T3 (es) Profármacos de carga de múltiples PAF
JP2023551145A (ja) 医薬化合物の錯化剤塩製剤
JP2011504964A5 (cg-RX-API-DMAC7.html)
JP2023552610A5 (cg-RX-API-DMAC7.html)
JP2005002123A5 (cg-RX-API-DMAC7.html)
FI3518960T3 (fi) Annostusohjelma kontrolloidusti vapautuvalle PTH-yhdisteelle
JP2004534774A5 (cg-RX-API-DMAC7.html)
JP2006519852A5 (cg-RX-API-DMAC7.html)
KR100891438B1 (ko) 무스카린 길항제와 선택된 오피오이드와의 배합물 및 이를 포함하는 요실금 치료용 약제학적 조성물
CA2607360C (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
JP2011511073A5 (cg-RX-API-DMAC7.html)
JP2007536241A5 (cg-RX-API-DMAC7.html)
RU2019139286A (ru) Фармацевтический состав
JP2008513524A5 (cg-RX-API-DMAC7.html)
JP2023538524A5 (cg-RX-API-DMAC7.html)
JP2005536503A5 (cg-RX-API-DMAC7.html)
JPWO2020022272A5 (cg-RX-API-DMAC7.html)
KR20190026003A (ko) 중수소화 덱스트로메토르판의 합성 방법
CA2569742A1 (en) Opioids for the treatment of the restless leg syndrome
JP2009521470A5 (cg-RX-API-DMAC7.html)
JP2009539822A5 (cg-RX-API-DMAC7.html)
RU2007122406A (ru) Производные тетралина и индана и их применения в качестве антагонистов 5-нт
JP2000516257A5 (cg-RX-API-DMAC7.html)
JP2009512676A5 (cg-RX-API-DMAC7.html)